K2 Medical Research

K2 Medical Research is a leading integrated clinical trial site platform specializing in high-complexity therapeutic areas, most notably central nervous system (CNS) disorders and metabolic diseases. Headquartered in Maitland, Florida, the company operates a multi-regional network of de novo research facilities that partner with premier pharmaceutical and biotechnology sponsors to conduct Phase I through Phase IV clinical trials. K2 distinguishes itself through advanced patient recruitment capabilities and its "Wanda" mobile research unit, which enhances trial diversity by bringing research opportunities to underserved communities. In June 2024, TPG Growth made a significant strategic investment in the company to accelerate its expansion into a leading national site platform. Having participated in more than 150 studies for major sponsors such as Eli Lilly, AbbVie, and Johnson & Johnson, K2 provides a critical link in the drug development value chain by ensuring high-quality data and efficient patient enrollment.